Five things for pharma marketers to know
- The Food and Drug Administration approved Novartis’ treatment for adults with a rare, serious blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH).
- Pfizer decided to leave the Biotechnology Innovation Organization, according to sources familiar with the planning.
- The head of Walmart said it’s too early to say exactly what effect the new class of weight-loss drugs that have become highly popular in the U.S. will have on consumer behavior.
- Coya Therapeutics said it will sell around $26.5 million worth of stock in a private placement that includes participation from former Secretary of Commerce Wilbur Ross, who is expected to join the biotech company’s board.
- The disappointing data Pfizer announced last week on its obesity pill are opening up opportunities for biotechs developing their own oral weight-loss drugs.
